NCT02313051View on ClinicalTrials.gov

Everolimus trIal for Advanced prememopausaL Breast Cancer Patients

PHASE2UnknownINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2017

Conditions

Metastatic Breast Cancer

Interventions

DRUG

Everolimus

mTOR inhibitor

DRUG

Goserelin

DRUG

Letrozole

Trial Locations (1)

100021

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Chinese Academy of Medical Sciences

OTHER